Trial Profile
A phase I open label safety and pharmacokinetic study of Navitoclax (ABT-263) in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2015
Price :
$35
*
At a glance
- Drugs Navitoclax (Primary) ; Carboplatin; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 26 Nov 2015 New trial record